Read by QxMD icon Read

radioactive iodine avidity

Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, MinJi Jeon, Jong Jin Lee, Jin-Sook Ryu, Tae Yong Kim, YoungKee Shong, Won Bae Kim
BACKGROUND: For patients with lung metastases of differentiated thyroid carcinoma (DTC), there is no consensus on the maximal size of metastatic lesions to use when determining the intensity of follow-up and additional therapeutic options. We evaluated the clinical outcomes and survival of patients with metastatic DTC confined to the lung, using the maximal diameter of lung lesions in the initial computed tomography (CT). METHODS: This retrospective cohort study included 112 DTC patients with metastases confined to the lung...
October 17, 2016: Thyroid: Official Journal of the American Thyroid Association
Desiree Deandreis, Carole Rubino, Hernan Tala, Sophie Leboulleux, Marie Terroir, Eric Baudin, Steve Larson, James A Fagin, Martin Schlumberger, Michael R Tuttle
: The optimal management of radioactive iodine (RAI) treatment in patients with metastatic thyroid cancer (TC) is still a matter of debate. METHODS: We retrospectively analyzed 352 patients with RAI avid metastatic well differentiated TC treated with (131)I by empiric fixed activity of 3.7 GBq at Gustave Roussy (GR, n = 231) or by personalized activity (2.8 to 18.6 GBq) based on whole body/blood clearance dosimetry (WB/BC) at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121)...
October 13, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin
: Telomerase Reverse Transcriptase (TERT) promoter mutation has been reported to be associated with aggressive characteristics in differentiated thyroid cancer (DTC). This study examined the status of TERT promoter mutation in distant metastatic DTC (DM-DTC), and evaluated the correlation between TERT mutation and radioactive iodine-131(RAI) uptake, as well as that between TERT mutation and therapy response. METHODS: TERT promoter and B-Raf proto-oncogene (BRAF) V600E mutation were retrospectively examined in primary tumors of 66 DM-DTC patients...
August 4, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Ling Li, Dongjian Zhang, Shengwei Yang, Shaoli Song, Jindian Li, Qin Wang, Cong Wang, Yuanbo Feng, Yicheng Ni, Jian Zhang, Wei Liu, Zhiqi Yin
PURPOSE: Sennidins are necrosis-avid agents for noninvasive assessment of myocardial viability which is important for patients with myocardial infarction (MI). However, high accumulation of radioactivity in the liver interferes with the assessment of myocardial viability. In this study, we compared sennidins with sennosides to investigate the effects of glycosylation on biodistribution and imaging quality of sennidins. PROCEDURES: Sennidin A (SA), sennidin B (SB), sennoside A (SSA), and sennoside B (SSB) were labeled with I-131...
May 12, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Christa L Jillard, Linda Youngwirth, Randall P Scheri, Sanziana Roman, Julie A Sosa
BACKGROUND: Hürthle cell carcinoma (HCC) is not typically iodine avid, raising questions regarding postoperative use of radioactive iodine (RAI). The aims of this study were to describe current practice patterns regarding the use of RAI for HCC and to assess its association with survival. METHODS: The National Cancer Data Base 1998-2006 was queried for all patients with HCC who underwent total thyroidectomy. Inclusion was limited to T1 tumors with N1/M1 disease, and T2-4 tumors with any N/M disease...
July 2016: Thyroid: Official Journal of the American Thyroid Association
Mona M Sabra, Ronald Ghossein, R Michael Tuttle
BACKGROUND: With the advent of molecular targeted therapy for the management of radioactive iodine (RAI) refractory, progressive metastatic thyroid cancer, it becomes important to define the time course and risk factors for structural disease progression in follicular cell-derived thyroid cancer (FCDTC) patients. This will help in defining the optimal time to start these therapies and better define their impact on structural disease progression. OBJECTIVES: This retrospective review of 199 consecutive patients with FCDTC presenting with lung metastasis examined the progression-free survival (PFS) in thyroid cancer patients with lung metastasis treated with surgery and RAI, and who had not received molecular targeted therapy or chemotherapy...
April 2016: Thyroid: Official Journal of the American Thyroid Association
Seza A Gulec, Russ A Kuker, Mohammed Goryawala, Carlos Fernandez, Rudolfo Perez, Alina Khan-Ghany, Ana Apaza, Evis Harja, Mack Harrell
BACKGROUND: Although radioactive iodine (RAI) imaging/therapy is one of the earliest applications of theranostics, there remain a number of unresolved clinical questions as to the optimization of diagnostic techniques/protocols and improvements in patient-specific treatment planning strategies. The objectives of this study were to determine the imaging characteristics and clinical feasibility of (124)I positron emission tomography/computed tomography (PET/CT) for the determination of extent of disease and evaluation of RAI kinetics in its physiologic and neoplastic distribution in patients with differentiated thyroid cancer (DTC)...
March 2016: Thyroid: Official Journal of the American Thyroid Association
Weiwei Cheng, Rengyun Liu, Guangwu Zhu, Hui Wang, Mingzhao Xing
CONTEXT: Use of BRAF V600E inhibitors to restore thyroid iodide-handling gene expression and radioactive iodine (RAI) avidity is an attractive therapeutic strategy for RAI-refractory thyroid cancer, but recent initial clinical responses were modest. Given histone deacetylation at the sodium/iodide symporter promoter by histone deacetylase (HDAC) as a mechanism, simultaneously targeting BRAF V600E and HDAC could be a more effective strategy. OBJECTIVES: The objective of the study was to test whether suppressing both BRAF V600E and HDAC could more effectively induce thyroid gene expression and RAI uptake in thyroid cancer cells...
March 2016: Journal of Clinical Endocrinology and Metabolism
Saima Riaz, Humayun Bashir, Aamna Hassan, Aamir Ali Syed, Mudassar Hussain, Saba Imtiaz
We report a case of 21 years old lady who presented with ascites, left adnexal mass and elevated CA-125. With suspicion of ovarian malignancy, she underwent left salpingo-oophorectomy with omental biopsy. Histopathology revealed: 'follicular variant of papillary thyroid carcinoma arising in struma ovarii' with metastatic papillary thyroid carcinoma in omental and peritoneal nodules. Patient underwent total thyroidectomy followed by radioactive iodine therapy for metastatic omental and peritoneal disease. Post-therapy whole body scan, revealed extensive I-131 avid disease metastatic disease involving the chest, abdomen, pelvis and the musculoskeletal system...
July 2015: Journal of Ayub Medical College, Abbottabad: JAMC
Ana P Kiess, Nishant Agrawal, James D Brierley, Umamaheswar Duvvuri, Robert L Ferris, Eric Genden, Richard J Wong, R Michael Tuttle, Nancy Y Lee, Gregory W Randolph
The use of external-beam radiotherapy (EBRT) in differentiated thyroid cancer (DTC) is debated because of a lack of prospective clinical data, but recent retrospective studies have reported benefits in selected patients. The Endocrine Surgery Committee of the American Head and Neck Society provides 4 recommendations regarding EBRT for locoregional control in DTC, based on review of literature and expert opinion of the authors. (1) EBRT is recommended for patients with gross residual or unresectable locoregional disease, except for patients <45 years old with limited gross disease that is radioactive iodine (RAI)-avid...
April 2016: Head & Neck
Kevin So, Robin E Smith, Sidney R Davis
BACKGROUND: The usual management of thyroid cancer is surgery and radioactive iodine. The role of external beam radiotherapy (EBRT) in well-differentiated thyroid carcinoma remains controversial. Indications for the use of EBRT, contained within both the American and British Thyroid Association published guidelines, include unresectable or non-iodine avid disease, extra-thyroidal extension or distant metastatic disease. METHODS: A retrospective review of prospectively collected data from a single Australian institution was conducted, analysing patients referred and treated with EBRT for well-differentiated thyroid carcinoma between November 1992 and July 2013...
September 2016: ANZ Journal of Surgery
Martijn R Meijerink, Hester J Scheffer, Remco de Bree, Robert-Jan Sedee
A 74-year-old man presented with a small locoregional, histopathologically proven, fluorodeoxyglucose positron emission tomography/computed tomography-avid recurrence of follicular thyroid carcinoma in the left subglottic space after extensive surgical resection, adjuvant radioactive iodine therapy, and external beam radiation therapy. Because all established focal therapies were contraindicated, percutaneous irreversible electroporation was performed without complications. Follow-up imaging at 7 months showed a small ablation scar without signs for residual vital tumor tissue...
August 2015: Journal of Vascular and Interventional Radiology: JVIR
Yi-Hong Zeng, Chi-Kuan Chen, Chun-Chuan Lee
A 54-year-old woman who had undergone total thyroidectomy and radioactive iodine treatment for papillary thyroid cancer presented with elevated stimulated thyroglobulin levels and negative I-131 scan. Ultrasonography revealed suspicious lateral neck lymph nodes, which were FDG-avid. Neck dissection led to a diagnosis of Castleman disease.
February 2016: Endocrine
Ryan P Goepfert, Chienying Liu, William R Ryan
BACKGROUND: Retropharyngeal metastases are uncommon but a well-known location for regional spread of well-differentiated thyroid carcinoma (WDTC). Surgeon-performed, trans-oral ultrasound (SP-TO-US) and trans-oral robot-assisted surgical (TORS) excision represent a unique combination of technology and techniques in the treatment of isolated retropharyngeal thyroid metastases. PATIENT FINDINGS: A patient with a history of T3N1b papillary thyroid carcinoma (PTC) previously treated with total thyroidectomy, left central and lateral neck dissection, and radioactive iodine presented with progressive elevations in serum thyroglobulin (Tg) from baseline of 0...
September 2015: American Journal of Otolaryngology
Rebecca Zeuren, Agnese Biagini, Ravinder K Grewal, Gregory W Randolph, Dipti Kamani, Mona M Sabra, Ashok R Shaha, R Michael Tuttle
OBJECTIVE: Recent, more selective use of radioactive iodine (RAI) has led to reevaluation of the clinical importance of achieving complete total thyroidectomy with minimal residual normal thyroid tissue. We utilize the improved localization by post-RAI remnant ablation, single photon emission computerized tomography-computed tomography (SPECT-CT) to define specific anatomic sites of residual RAI-uptake foci after total thyroidectomy for differentiated thyroid cancer (DTC) and to provide a novel classification system relating uptake to thyroid anatomy and preservation of adjacent neural structures...
October 2015: Laryngoscope
Camila Nascimento, Isabelle Borget, Abir Al Ghuzlan, Désirée Deandreis, Dana Hartl, Jean Lumbroso, Amandine Berdelou, Charlotte Lepoutre-Lussey, Haïtham Mirghani, Eric Baudin, Martin Schlumberger, Sophie Leboulleux
BACKGROUND: Aggressive histopathologic subtypes of differentiated thyroid cancer (DTC) are fluorodeoxyglucose (FDG)-avid tumors and are at high risk for persistent/recurrent disease. In these patients, fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is performed in cases of suspicion of recurrence based on thyroglobulin (Tg) levels or thyroglobulin antibodies (TgAb). The goals of this study were to evaluate the sensitivity of systematic postoperative FDG-PET/CT and to identify risk factors for abnormal FDG-PET/CT...
April 2015: Thyroid: Official Journal of the American Thyroid Association
Xuejiao Liu, Cuihua Jiang, Yue Li, Wei Liu, Nan Yao, Meng Gao, Yun Ji, Dejian Huang, Zhiqi Yin, Ziping Sun, Yicheng Ni, Jian Zhang
Hypericin (Hy) has shown great promise as a necrosis-avid agent in cancer imaging and therapy. Given the highly hydrophobic and π-conjugated planarity characteristics, Hy tends to form aggregates. To investigate the effect of aggregation on targeting biodistribution, nonaggregated formulation (Non-Ag), aggregated formulation with overconcentrated Hy in dimethyl sulfoxide (Ag-DMSO) solution, and aggregated formulation in water solution (Ag-water) were selected by fluorescence measurement. They were labeled with ¹³¹I and evaluated for the necrosis affinity in rat model of reperfused hepatic infarction by gamma counting and autoradiography...
January 2015: Journal of Pharmaceutical Sciences
Dongjian Zhang, Dejian Huang, Yun Ji, Cuihua Jiang, Yue Li, Meng Gao, Nan Yao, Xuejiao Liu, Haibo Shao, Su Jing, Yicheng Ni, Zhiqi Yin, Jian Zhang
Necrosis-avid agents are a class of compounds that selectively accumulate in the necrotic tissues after systemic administration, which can be used for in vivo necrosis imaging and targeted therapies. In order to search for a necrosis-avid tracer agent with improved drugability, we labelled iodine-131 on sennoside B (SB) as a naturally occurring median dianthrone compound. The necrosis targetability and clearance properties of (131)I-SB were evaluated in model rats with liver and muscle necrosis. On SPECT/CT images, a "hot spot" in the infarcted liver lobe and necrotic muscle was persistently observed at 24 h and 72 h post-injection (p...
February 2015: Journal of Drug Targeting
Norra Kwong, Ellen Marqusee, Michael S Gordon, P Reed Larsen, Jeffrey R Garber, Matthew I Kim, Erik K Alexander
Well-differentiated thyroid carcinoma (WDTC) generally has a favorable prognosis. However, patients with distant metastatic disease experience progression of disease with a higher mortality. A subset of patients not previously described may challenge the conventional dogma regarding the progressive nature of all metastatic WDTC. Through analysis of our database, we identified patients with distant metastatic WDTC and persistent, minimally progressive disease. In all patients, persistent metastatic disease was confirmed via tissue biopsy, abnormal PET scan, and/or biochemical elevations in thyroglobulin or antibody levels...
December 2014: Endocrine Connections
Marlein Miranda Cona, Peter de Witte, Alfons Verbruggen, Yicheng Ni
Translational medicine pursues the conversion of scientific discovery into human health improvement. It aims to establish strategies for diagnosis and treatment of diseases. Cancer treatment is difficult. Radio-pharmaceutical research has played an important role in multiple disciplines, particularly in translational oncology. Based on the natural phenomenon of necrosis avidity, OncoCiDia has emerged as a novel generic approach for treating solid malignancies. Under this systemic dual targeting strategy, a vascular disrupting agent first selectively causes massive tumor necrosis that is followed by iodine-131 labeled-hypericin ((123)I-Hyp), a necrosis-avid compound that kills the residual cancer cells by crossfire effect of beta radiation...
December 26, 2013: World Journal of Methodology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"